{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T00:42:25Z","timestamp":1784421745593,"version":"3.55.0"},"reference-count":3,"publisher":"Wiley","issue":"22","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2025,11,15]]},"abstract":"<jats:p>\n                    This news section offers\n                    <jats:italic>Cancer<\/jats:italic>\n                    readers timely information on events, public policy analysis, and topical issues. In this issue, the FDA grants a fourth bispecific antibody, linvoseltamab, accelerated approval for relapsed or refractory multiple myeloma, and a weekly injection is a potential new treatment option for polycythemia vera. In addition, adding adjuvant nivolumab improved disease\u2010free survival for patients with high\u2010risk locally advanced HNSCC, and switching to camizestrant prolonged PFS for patients with ER\u2010positive, HER2\u2010negative advanced breast cancer and an\n                    <jats:italic>ESR1<\/jats:italic>\n                    mutation.\n                  <\/jats:p>","DOI":"10.1002\/cncr.70108","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T13:55:27Z","timestamp":1763387727000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["FDA grants a fourth bispecific antibody, linvoseltamab, accelerated approval for relapsed or refractory multiple myeloma"],"prefix":"10.1002","volume":"131","author":[{"given":"Leah","family":"Lawrence","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"e_1_2_2_2_1","unstructured":"FDA grants accelerated approval to linvoseltamab\u2010gcpt for relapsed or refractory multiple myeloma. US Food and Drug Administration.July 2 2025. Accessed August 6 2025.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010accelerated\u2010approval\u2010linvoseltamab\u2010gcpt\u2010relapsed\u2010or\u2010refractory\u2010multiple\u2010myeloma"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643\u20103230.BCD\u201023\u20100176"},{"key":"e_1_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.0100"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T06:06:21Z","timestamp":1765001181000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70108"}},"subtitle":["The approval of linvoseltamab likely also benefits from the fact that \u201cover time we have learned how to give these drugs in a safer way.\u201d\u2014Ajay K. Nooka, MD, MPH"],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":3,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2025,11,15]]}},"alternative-id":["10.1002\/cncr.70108"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70108","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"2025-11-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70108"}}